As of 3:59pm ET
| +0.13 / +0.40%|
The 13 analysts offering 12-month price forecasts for Revance Therapeutics Inc have a median target of 39.00, with a high estimate of 65.00 and a low estimate of 20.00. The median estimate represents a +20.89% increase from the last price of 32.26.
The current consensus among 13 polled investment analysts is to Buy stock in Revance Therapeutics Inc. This rating has held steady since March, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.